Anticoagulation for New Atrial Fibrillation After CABG
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Recruiting
Phase 3
Interventional Study
Atrial Fibrillation
Stroke
Bleeding
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 3,200 (estimated)
- Sponsor
- Icahn School of Medicine at Mount Sinai · Other
Who this trial is looking for
This trial is looking for patients who develop new atrial fibrillation after heart bypass surgery. Participants will receive a treatment to help prevent blood clots while monitoring their safety and health.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old
- I have had heart bypass surgery
- I have had atrial fibrillation that lasted more than 60 minutes or happened more than once within 7 days after surgery
You may not be able to join if
- I have a history of permanent or persistent atrial fibrillation
- I need long-term anticoagulation therapy
- I have major complications from my surgery
- I am planning to take dual antiplatelet therapy after surgery
- I have liver cirrhosis or severe liver disease
- I am pregnant
- I cannot provide informed consent
- I have a disease that limits my life expectancy to less than one year
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline r…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients of age ≥18 years who undergo isolated CABG for coronary artery disease
* POAF that persists for \>60 minutes or is recurrent (more than one episode) within 7 days after the index CABG surgery
Exclusion Criteria:
* Clinical history of either permanent, persistent or …
Contacts